key: cord-1033555-wbso4fci
authors: Cao, Yunlong; Yisimayi, Ayijiang; Jian, Fanchong; Song, Weiliang; Xiao, Tianhe; Wang, Lei; Du, Shuo; Wang, Jing; Li, Qianqian; Chen, Xiaosu; Wang, Peng; Zhang, Zhiying; Liu, Pulan; An, Ran; Hao, Xiaohua; Wang, Yao; Wang, Jing; Feng, Rui; Sun, Haiyan; Zhao, Lijuan; Zhang, Wen; Zhao, Dong; Zheng, Jiang; Yu, Lingling; Li, Can; Zhang, Na; Wang, Rui; Niu, Xiao; Yang, Sijie; Song, Xuetao; Zheng, Linlin; Li, Zhiqiang; Gu, Qingqing; Shao, Fei; Huang, Weijin; Jin, Ronghua; Shen, Zhongyang; Wang, Youchun; Wang, Xiangxi; Xiao, Junyu; Xie, Xiaoliang Sunney
title: BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
date: 2022-05-02
journal: bioRxiv
DOI: 10.1101/2022.04.30.489997
sha: e70c95db58b7d01dca5662f505efa1ad3ba7a8e1
doc_id: 1033555
cord_uid: wbso4fci

The recently emerged SARS-CoV-2 Omicron sublineages BA.2.12.1, BA.2.13, BA.4 and BA.5 all contain L452 mutations and show potential higher transmissibility over BA.21. The new variants’ receptor binding and immune evasion capability require immediate investigation, especially on the role of L452 substitutions. Herein, coupled with structural comparisons, we show that BA.2 sublineages, including BA.2.12.1 and BA.2.13, exhibit increased ACE2-binding affinities compared to BA.1; while BA.4/BA.5 displays the weakest receptor-binding activity due to F486V and R493Q reversion. Importantly, compared to BA.2, BA.2.12.1 and BA.4/BA.5 exhibit stronger neutralization evasion against the plasma of 3-dose vaccinees and, most strikingly, of vaccinated BA.1 convalescents. To delineate the underlying evasion mechanism, we determined the escaping mutation profiles2, epitope distribution3 and Omicron sublineage neutralization efficacy of 1640 RBD-directed neutralizing antibodies (NAbs), including 614 isolated from BA.1 convalescents. Interestingly, post-vaccination BA.1 infection mainly recalls wildtype (WT) induced humoral memory and elicits antibodies that neutralize both WT and BA.1. These cross-reactive NAbs are significantly enriched on non-ACE2-competing epitopes; and surprisingly, the majority are undermined by R346 and L452 substitutions, namely R346K (BA.1.1), L452M (BA.2.13), L452Q (BA.2.12.1) and L452R (BA.4/BA.5), suggesting that R346K and L452 mutations appeared under the immune pressure induced by Omicron convalescents. Nevertheless, BA.1 infection can also induce new clones of BA.1-specific antibodies that potently neutralize BA.1 but do not respond to WT SARS-CoV-2 due to the high susceptibility to N501, N440, K417 and E484. However, these NAbs are largely escaped by BA.2 sublineages and BA.4/BA.5 due to D405N and F486V, exhibiting poor neutralization breadths. As for therapeutic NAbs, LY-CoV1404 (Bebtelovimab4) and COV2-2130 (Cilgavimab5) can still effectively neutralize BA.2.12.1 and BA.4/BA.5, while the S371F, D405N and R408S mutations carried by BA.2/BA.4/BA.5 sublineages would undermine most broad sarbecovirus NAbs. Together, our results indicate that Omicron can evolve mutations to specifically evade humoral immunity elicited by BA.1 infection. The continuous evolution of Omicron poses great challenges to SARS-CoV-2 herd immunity and suggests that BA.1-derived vaccine boosters may not be ideal for achieving broad-spectrum protection.

against Omicron subvariants (Fig. 2e) . All of the seven Omicron subvariants displayed striking Fig. 2a) 25, 30 . First, antigen-specific memory B cells were isolated by distributed stochastic neighbor embedding (t-SNE) (Fig. 3a) , adding 6 more epitope groups 1 compared to our previous classification 3 .

Group A-C recapitulates our previous taxonomy 3 , in which the members mainly target the ACE2-4 binding motif [33] [34] [35] [36] [37] (Extended Data Fig. 3a) . Group D antibodies, such as REGN10987, CoV1404 and COV2-2130, bind to the linear epitope 440-449 on the RBD and are expanded into 6 D1 and D2 subgroups. Group D1 is more affected by R346 and L452, while D2 antibodies do not 7 (Extended Data Fig. 3b) . Additionally, Group E and F are now expanded into E1-E3 and F1-F3, 8 which covers the front and backside of RBD, roughly corresponding to Class 3 and Class 4, 9 respectively 36 (Extended Data Fig. 3a ). Group E1 corresponds to the S309 binding site, whose 10 epitope involves G339 and R346 (Extended Data Fig. 3b ). Group E2 antibodies bind to the front 11 chest of RBD 34 and do not compete with ACE2 (Fig. 3d) , where E2.1 is more affected by R346 12 and A348, while E2.2 is more affected by R357 (Extended Data Fig. 3a-c) . Group E3 (S2H97 site) 13 and F1 (S304 site) bind to highly conserved regions on the bottom of RBD, mainly contacting with Table 2 and Supplementary Table 3 ). We 22 found that antibodies of the same cluster have unified sarbecovirus neutralization potency and 23 binding spectra (Fig. 3e, Extended Data Fig. 4 ). In total, five clusters of antibodies exhibiting broad 24 sarbecovirus binding ability were identified, namely Groups E1, E3, F1, F2 and F3 (Extended Data 25 Fig. 4) , of which E1, F2 and F3 showed potent neutralizing activity against SARS-CoV-1 (Fig.3e) .

We found that compared to WT convalescents or vaccinees, the plasma of vaccinated SARS 1 convalescents enriched Group E1, E3, F1, F2 and F3 antibodies, which bind conserved epitopes 2 among sarbecoviruses and display broad sarbecovirus neutralizing activity (Fig. 3b-c) . However, 3 revealed by DMS, we know that F2 and F3 antibodies are susceptible to D405N and R408S 4 mutations (Extended Data Fig. 3b) , and BA.2 sublineages and BA.3/BA.4/BA.5 may dampen 5 those NAbs, explaining the sharp drop of plasma NT50 against Omicron variants other than BA.1 6 sublineages (Fig. 2d) . Importantly, we also found that the humoral immunity elicited by post- suggesting a higher affinity maturation (Fig. 3f) .

Most WT-stimulated Group A, B and C antibodies were largely escaped by Omicron variants, 22 while a subset showed broad Omicron effectiveness (Fig. 3f) . These antibodies are largely enriched 23 in BA.1-stimulated groups and generally use similar heavy chain V genes compared to WT-24 stimulated antibodies, but display higher convergence (Extended Data Fig. 5a-b) . These broad 25 NAbs in groups A, B and C are also shown to be enriched in individuals who received a booster 26 dose of mRNA vaccines 38 , which probably accounts for the high plasma neutralizing activity of 3-1 dose mRNA vaccinees against Omicron variants. Nevertheless, BA.1-stimulated groups B and C 2 NAbs were significantly evaded by BA.4 due to F486V and L452R, concordant with results from 3 DMS (Extended Data Fig. 6a-b) . 4 Group D antibodies are most affected by G446S in BA.1, BA.1.1 and BA.3; thus, these NAbs 5 showed higher potency against BA.2 ( Fig. 4a- Fig. 7a ). However, the linear epitope of these antibodies is not conserved (Fig. 4d) , suggesting 11 that their good breadth is possibly due to their rarity in WT and BA.1 convalescents (Fig. 3b) .

12 13 E2 antibodies bind to the chest of RBD 34 (Fig. 4a) , and their epitopes focus around R346, A348, 14 A352, K356, R357 and I468 (Fig. 4d) . Despite similar epitopes, E2.1 antibodies, especially those 15 BA.1-stimulated, display significantly higher neutralizing potency than E2.2 ( Fig. 4b and   16 Extended Data Fig. 8a-b) . Interestingly, L452 substitutions also cause large-scale escapes of E2.1 17 and E2.2 antibodies (Fig. 4c ). Similar to the D1 epitope group, L452R and L452Q cause much 18 stronger antibody evasion than L452M (Fig. 4c) 

In total, five clusters of antibodies were found to exhibit broad sarbecovirus neutralizing ability 1 with diverse breadth, namely Group E1, E3, F1, F2 and F3 (Fig, 3e and Extended Data Fig. 4 ).

2 However, we found that BA.1-effective E1, F2 and F3 NAbs displayed a systematic reduction in 3 neutralization activity against BA.2 subvariants and BA.3/BA.4/BA.5 ( Fig. 2e and 5a-c) , while 4 Group E3 and F1 antibodies demonstrated weak neutralizing activity against all variants (Fig. 3f   5 and Extended Data Fig. 8a ) due to their highly conserved binding sites (Extended Data Fig. 8b-c) . 6 The mechanisms behind the neutralization loss of those broad sarbecovirus antibodies are unclear 7 and require investigation, which is critical for developing broad-spectrum sarbecovirus vaccines 8 and antibody therapeutics. To study why BA.2 subvariants and BA.3/BA.4/BA.5 could systematically reduce the 10 neutralization efficacy of E1 antibodies, we solved the cryo-EM structures of two BA.1 11 neutralizing E1 antibodies, BD55-3152 and BD55-5840 (SA58), in complex with BA.1 spike 12 proteins using cryo-electron microscopy (cryo-EM) (Fig. 5f , Extended Data Fig. 9a and 9c) . Like 13 S309, E1 antibodies' epitope involves an N-linked glycan on N343 (Fig. 5f ). Besides, members of 14 Group E1 are generally sensitive to the changes of G339, E340, T345 and especially R346, 15 revealed by their escaping mutation profiles (Fig. 5e) . Intriguingly, the newly acquired mutations 16 of BA.2 do not overlap with the shared epitope of E1 antibodies, suggesting that the systematic 17 reduction of neutralization is not caused by amino-acid substitution, but potentially due to 18 structural alteration. To explore this hypothesis, we further determined the cryo-EM structure of 19 the prefusion-stabilized BA.2 spike in complex with the BD55-5840 Fab (Fig. 5g) . A structural 20 comparison with the BA.1 RBD binding to BD55-5840 described above suggests that the 366-377 21 hairpin loop displays significant conformational differences due to S371F and T376A mutations 22 (Fig. 5g) . As a result, the bulky Phe resulting from the S371F mutation interferes with the 23 positioning of the glycan moiety attached to N343, which in turn budges the heavy chain of BD55-24 5840 upward. This may explain the reduction of the binding of BD55-5840 and S309, rationalizing 25 their reduced neutralizing activity ( Fig. 5a and Extended Data Fig. 9b) . Importantly, the N343 26 glycan is critically recognized by almost all E1 neutralizing antibodies, including S309. Thus, this 27 group of broad and potent neutralizing antibodies is likely affected by the S371F mutation in a 1 systematic manner through N343-glycan displacement.

The epitopes of group F2 and F3 antibodies cover a continuous surface on the backside of RBD 4 and can only bind to the up RBDs (Fig. 2b) . To probe how BA.2 escapes antibodies of group F2 5 and F3, we solved the cryo-EM structure of two representative BA.1-effective antibodies in these 6 groups, BD55-1239 from group F2, and BD55-3372 from group F3, in complex with the BA.1 and 7 Delta spike protein respectively (Fig. 5h -i and Extended Data Fig. 9a ). Group F2 antibodies can 8 be escaped by RBD mutation involving T376, K378, and R408 (Fig. 5e) . Indeed, these residues 9 are all at the heart of BD55-1239's epitope, and are fairly conserved across sarbecoviruses ( Fig.   10 5e). Importantly, D405N and R408S harbored by Omicron BA.2 sublineages could alter the 11 antigenic surface that disrupts the binding of F2 antibodies (Fig. 5i) , hence completely abolishing 12 the neutralizing capacity of F2 antibodies (Fig. 5b) . Similarly, the D405N and R408S mutations 

Besides all those NAbs that could bind to WT, it is also important to investigate the epitope 1 distribution of BA.1-specific NAbs that do not react with WT RBD. To do so, we built the yeast 2 display variants library based on RBD BA.1, and determined the escape mutation maps of 102 3 BA.1-specific antibodies. By integrating analysis of the whole dataset containing 1640 SARS-4 CoV-2 RBD antibodies, we got the embedded features of the BA.1-specific NAbs and performed 5 clustering and t-SNE similarly. The 102 NAbs were clustered into four BA.1-specific epitope 6 groups, named A Omi , B Omi , D Omi , and F3 Omi (Fig. 6a) , because these groups are highly related to 7 their corresponding WT epitope groups (Fig. 6d) . These antibodies are all ACE2-competing and 8 cannot neutralize D614G and SARS-CoV-1 (Fig. 6b) , probably due to N417K/Y501N/H505Y for contributes to a small subset of A Omi antibodies. Instead, D Omi antibodies were dominant by 20 IGHV2-70 and IGHV5-51, while IGHV4-59 for F Omi (Extended Data Fig. 10a ). These three V 21 genes also appeared in WT-reactive antibodies, but were relatively rare and did not show 22 significant epitope enrichment (Extended Data Fig. 5a-b) .

In this study, we showed that Omicron is continuously evolving under immune pressure, and Here, by combining high-throughput single-cell sequencing and high-throughput yeast display-6 based deep mutational screening, we showcased the ability to decipher the complicated humoral (n=28). P-values were calculated using a two-tailed Wilcoxon signed-rank test, in comparison to IC50 against BA.2. *, <0.05; **, <0.01; ***, <0.001; n.s., not significant. e, Neutralizing activity against SARS-CoV-2 variants and sarbecoviruses by therapeutic neutralizing antibodies. green, IC50 < 30ng/mL; red, IC50 > 1,000ng/mL; *, IC50 > 10,000ng/mL. f, 

Clade 2 T95I  G142D  del143-145  N211I  del212  V213G  G339D  R346K  S371L  S371F  S373P  S375F  T376A  D405N  R408S  K417N  N440K  G446S  L452M  L452Q  L452R  S477N  T478K  E484A  F486V  Q493R  G496S  Q498R  N501Y  Y505H  T547K  D614G  H655Y  N679K  P681H  S704L  N764K  D796Y  N856K  Q954H  N969K  L981F   a   b Extended Data Fig. 1 Extended Data Fig. 1 357  361  365  369  374  378  381  383  384  385  386  390  391  392  393  394  396  428  462  464  465  468  514  516 518 519 Fig. 8 Extended Data Fig. 8 

a, Neutralizing activity against SARS-CoV-2 D614G and Omicron subvariants by antibodies in group E3 and F1.

Geometric mean of IC50 (μg/mL) are annotated above the bars. P-values were calculated using a two-tailed High-throughput antibody-escape mutation profiling 14 The previously described high-throughput MACS (magnetic-activated cell sorting)-based 15 antibody-escape mutation profiling system 3,17 was used to characterize mutation escape profile for collected with Octet Acquisition 9.0 (Fortebio) and analyzed by Octet Analysis 9.0 (Fortebio) and

Octet Analysis Studio 12.2 (Fortebio).

The thermal stability assay was performed to detect the exposed hydrophobic residues by an from 100 to 6.25 nM. The response units were recorded at room temperature and the resulting data 10 were fitted to a 1:1 binding model using Biacore Evaluation Software (GE Healthcare).

Protein expression and purification for cryo-EM study 13 The S6P expression construct encoding the SARS-CoV-2 spike ectodomain (residues 1-1208) with Cryo-EM data collection, processing, and structure building 11 The samples for cryo-EM study were prepared essentially as previously described 15,47

(Supplementary Table 4 ). All EM grids were evacuated for 2 min and glow-discharged for 30 s 13 using a plasma cleaner (Harrick PDC-32G-2). Four microliters of spike protein (0.8 mg/mL) was 14 mixed with the same volume of Fabs (1 mg/mL each), and the mixture was immediately applied 15 to glow-discharged holy-carbon gold grids (Quantifoil, R1. Data availability 26 Processed mutation escape scores can be downloaded at https://github.com/jianfcpku/SARS-CoV- 

CoV-Spectrum: analysis of globally shared SARS-CoV-2 data to identify and characterize new variants

Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain 443-449

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization

Effectiveness of BNT162b2 Vaccine against 5

Omicron Variant in South Africa

Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine 8 recipients

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing 12 antibody responses

Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2

Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients 18 receiving monoclonal antibodies

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected 22

Hamsters and Provides a Potent Cocktail Pairing Strategy

Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2

Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints 27 on Folding and ACE2 Binding

Antibody evasion properties of SARS-CoV-2 Omicron sublineages

Virological characteristics of SARS-CoV-2 BA.2 variant. bioRxiv

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry

Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and 12 RBD-subunit vaccines

SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape

Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies

Tackling COVID-19 with neutralizing monoclonal antibodies

The antigenic anatomy of SARS-CoV-2 receptor binding domain

Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-682-687

Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants

Integrated analysis of multimodal single-cell data

Shifting mutational constraints in the SARS-CoV-2 receptor-binding domain during viral 4 evolution. bioRxiv

Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite 6 conformational state for receptor binding

Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design 8 against concerning variants

cryoSPARC: algorithms for rapid unsupervised 10 cryo-EM structure determination

UCSF Chimera--a visualization system for exploratory research and analysis

New tools for automated high-resolution cryo-EM structure determination in RELION-3

Features and development of Coot. Acta 16 crystallographica. Section D

Macromolecular structure determination using X-rays, neutrons and electrons: recent 19 developments in Phenix

Structure visualization for researchers